{
  "id": 1743705,
  "title": "BioMarin acquires experimental drug for rare bone disorder in $275M deal",
  "url": "https://urgent.news/2026/08/18/biomarin-acquires-experimental-drug-for-rare-bone-disorder-in-275m",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T15:50:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/biomarin-alesta-deal-acquisition-rare-disease-muscle-skeleton/828133/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}